
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Kuan Peng, Joseph E. Blais, Nicole Pratt, et al.
BioDrugs (2023) Vol. 37, Iss. 3, pp. 409-420
Open Access | Times Cited: 5
Kuan Peng, Joseph E. Blais, Nicole Pratt, et al.
BioDrugs (2023) Vol. 37, Iss. 3, pp. 409-420
Open Access | Times Cited: 5
Showing 5 citing articles:
Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis
Kuan Peng, Shirley Chiu Wai Chan, Yang Wang, et al.
JAMA Network Open (2024) Vol. 7, Iss. 6, pp. e2418800-e2418800
Open Access | Times Cited: 7
Kuan Peng, Shirley Chiu Wai Chan, Yang Wang, et al.
JAMA Network Open (2024) Vol. 7, Iss. 6, pp. e2418800-e2418800
Open Access | Times Cited: 7
Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries
Alexander C. T. Tam, Jasleen Badesha, Daphne Guh, et al.
BioDrugs (2025)
Closed Access
Alexander C. T. Tam, Jasleen Badesha, Daphne Guh, et al.
BioDrugs (2025)
Closed Access
Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries
Hyunjung Woo, Gyeongseon Shin, Donghwan Lee, et al.
BioDrugs (2023) Vol. 38, Iss. 1, pp. 133-144
Open Access | Times Cited: 5
Hyunjung Woo, Gyeongseon Shin, Donghwan Lee, et al.
BioDrugs (2023) Vol. 38, Iss. 1, pp. 133-144
Open Access | Times Cited: 5
Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023
Qiyou Wu, Zhitao Wang, Yihan Fu, et al.
Global Health Research and Policy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Qiyou Wu, Zhitao Wang, Yihan Fu, et al.
Global Health Research and Policy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012–19
Hui-Han Chen, Tatenda T. Yemeke, Sachiko Ozawa
PLoS ONE (2024) Vol. 19, Iss. 6, pp. e0304851-e0304851
Open Access | Times Cited: 1
Hui-Han Chen, Tatenda T. Yemeke, Sachiko Ozawa
PLoS ONE (2024) Vol. 19, Iss. 6, pp. e0304851-e0304851
Open Access | Times Cited: 1